Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

34 results about "Deep fungal infection" patented technology

Novel voriconazole broad-spectrum antifungal medicine compound, broad-spectrum antifungal medicine composition and application thereof

The invention relates to a novel broad-spectrum antifungal medicine compound, a broad-spectrum antifungal medicine composition, an application of the compound or the composition in the preparation of a broad-spectrum antifungal medicine, and an application of the compound or the composition in the preparation of a medicine used for treating severe invasive infection (comprising Candida krusei) caused by invasive aspergillosis and / or Fluconazole-resistant Monilia and / or severe infection caused by Scedosporium and fusarium. The novel broad-spectrum antifungal medicine compound and the broad-spectrum antifungal medicine composition have extensive and strong antifungal activity and better dynamic property and safety. For deep mycotic infection, the novel broad-spectrum antifungal medicine compound and the broad-spectrum antifungal medicine composition are better than the original voriconazole in the aspects of the antibiotic activity and the medicine resistance and is better than amphotericin B in the aspects of safety and effectiveness; and compared with the formerly applied voriconazole, Fluconazole, itraconazole and amphotericin B, the novel broad-spectrum antifungal medicine compound and the broad-spectrum antifungal medicine composition have reinforced medicine effect, less adverse reaction and good safety.
Owner:LIVZON PHARM GRP INC

Terbinafine nano milk-like liquid antifungal medicine and its preparation

The invention discloses a terbinafine nanometer antifungal which is prepared by terbinafine, oil, surfactant, water according to the following method: First, the said raw materials are unloaded and weighed and reserved, then surfactants and oil is blended and mixed; terbinafine is added into cosurfactant and completely dissolved; the solution with terbinafine dissolved in it is added to the homogeneous mixed surfactant and oil, stirring uniform, finally, distilled water is slowly added dropwise, dropwising and stirring until the stable, homogeneous, transparent terbinafine nanometer antifungal is obtained. The drug with small particles, small viscosity, good fluidity and good nature stability, can reach through the skin and get into the blood circulation, inhibit squalene cycloxygenase, so as to treat the dermatophyte infection and many deep mycotic infection with a drastic therapeutic effect, and what is more the preparation of the invented products is simple, low energy consumption and without special equipment the drug can be mass produced.
Owner:NORTHWEST A & F UNIV

Application of lysine as synergist for preparing antifungal drug

The invention relates to the medical technology field, and discloses an application of lysine as a synergist for preparing antifungal drugs like polyenes or echinocandins. The antifungal drugs may be amphotericin B, nystatin or caspofungin. The amount of lysine or pharmaceutically acceptable salts thereof in the antifungal drug effective concentration is 0.03-0.5mM. As shown in an experiment, the combination application of antifungal drugs like amphotericin B, nystatin and caspofungin, can also ensure the treatment effect on superficial and deep fungal infections in case of decrease of drug dose, and the combination can be used as a synergist of the antifungal drugs. The lysine, as the synergist of the antifungal drugs, can decrease the medical dosage of the antifungal drugs like polyenes or echinocandins, thereby alleviating the toxic and side effect of medicaments, effectively treating fungal infection, and having a high application value.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY

Technology for purifying medicines for treating deep fungal infection

The invention discloses a technology for purifying medicines for treating deep fungal infection. The technology is characterized in that the technology comprises the following steps: 1, adding one-hundred-million amphotericin B to a mixed solvent of dimethyl formamide and a 180% methanol solution, and adjusting the pH value of the resulting solution; 2, preprocessing a macroporous absorbent resin A and a macroporous absorbent resin B which have different polarities with the dimethyl formamide and ethanol, mixing the resin A with the resin B according to a resin A/resin B ratio of 3:4-5:6, packing the resulting mixed resin to a chromatographic column having a column length-diameter ratio of 12.5:1 through using a wet packing method to obtain a mixed resin column, allowing a filtrate obtained in step 1 to pass through the mixed resin column, mixing the filtrate passing through the mixed resin column with dichloromethane and injection water according to a ratio of the amphotericin B to the dichloromethane to the injection water of one hundred million:10-20ml:10-25ml, adjusting the pH of the resulting solution with an acid or an alkali to 4.0-6.0, crystallizing, maintaining the temperature at 35-45DEG C after crystal generation, and carrying out crystal growing through allowing crystals to stand for 18-24h; and 3, carrying out suction filtration on the solution obtained after the crystal growing, and drying at 40-60DEG C for 24-30h to obtain products. The technology solves problems of low yield, complex technology and high cost of traditional recrystallization methods, and solves disadvantages of use of a single resin to purify, long column passing time, large resin consumption amount, and unsatisfactory effect.
Owner:SHANGHAI NEW ASIA PHARMA

Application of sodium houttuyfonate as synergist of antifungal medicament

The invention relates to the technical field of medicaments, in particular to novel application of sodium houttuyfonate as a synergist of an antifungal medicament. The antifungal medicament is an azole or polyene antifungal medicament; and 1 to 16mu g of sodium houttuyfonate is added into each 1ml of antifungal medicament. Experiments prove that: when the sodium houttuyfonate is combined with the antifungal medicament such as fluconazole, ketoconazole, miconazole or amphotercin B, and the like, the treatment effect of the sodium houttuyfonate on superficial or deep fungal infection can be ensured under the condition of reducing the dosage and the sodium houttuyfonate can make the antifungal medicament recover the effect on medicament-resistant fungi, so the sodium houttuyfonate can be used as the synergist of the antifungal medicament. The sodium houttuyfonate serving as the synergist of the antifungal medicament can reduce the dosage of the azole or polyene antifungal medicament so as to reduce the toxic and side effects of the medicament; and particularly, the sodium houttuyfonate makes the antifungal medicament recover the effect on the medicament-resistant fungi, effectively treats fungal infection, particularly medicament-resistant fungal infection, and has important clinical application value.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY

Application of sodium houttuyfonate as synergist of antifungal medicament

The invention relates to the technical field of medicaments, in particular to novel application of sodium houttuyfonate as a synergist of an antifungal medicament. The antifungal medicament is an azole or polyene antifungal medicament; and 1 to 16mu g of sodium houttuyfonate is added into each 1ml of antifungal medicament. Experiments prove that: when the sodium houttuyfonate is combined with theantifungal medicament such as fluconazole, ketoconazole, miconazole or amphotercin B, and the like, the treatment effect of the sodium houttuyfonate on superficial or deep fungal infection can be ensured under the condition of reducing the dosage and the sodium houttuyfonate can make the antifungal medicament recover the effect on medicament-resistant fungi, so the sodium houttuyfonate can be used as the synergist of the antifungal medicament. The sodium houttuyfonate serving as the synergist of the antifungal medicament can reduce the dosage of the azole or polyene antifungal medicament so as to reduce the toxic and side effects of the medicament; and particularly, the sodium houttuyfonate makes the antifungal medicament recover the effect on the medicament-resistant fungi, effectively treats fungal infection, particularly medicament-resistant fungal infection, and has important clinical application value.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY

A purification process of medicine for treating deep fungal infection

The invention discloses a technology for purifying medicines for treating deep fungal infection. The technology is characterized in that the technology comprises the following steps: 1, adding one-hundred-million amphotericin B to a mixed solvent of dimethyl formamide and a 180% methanol solution, and adjusting the pH value of the resulting solution; 2, preprocessing a macroporous absorbent resin A and a macroporous absorbent resin B which have different polarities with the dimethyl formamide and ethanol, mixing the resin A with the resin B according to a resin A / resin B ratio of 3:4-5:6, packing the resulting mixed resin to a chromatographic column having a column length-diameter ratio of 12.5:1 through using a wet packing method to obtain a mixed resin column, allowing a filtrate obtained in step 1 to pass through the mixed resin column, mixing the filtrate passing through the mixed resin column with dichloromethane and injection water according to a ratio of the amphotericin B to the dichloromethane to the injection water of one hundred million:10-20ml:10-25ml, adjusting the pH of the resulting solution with an acid or an alkali to 4.0-6.0, crystallizing, maintaining the temperature at 35-45DEG C after crystal generation, and carrying out crystal growing through allowing crystals to stand for 18-24h; and 3, carrying out suction filtration on the solution obtained after the crystal growing, and drying at 40-60DEG C for 24-30h to obtain products. The technology solves problems of low yield, complex technology and high cost of traditional recrystallization methods, and solves disadvantages of use of a single resin to purify, long column passing time, large resin consumption amount, and unsatisfactory effect.
Owner:SHANGHAI NEW ASIA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products